DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Weiqing WangBue F Ross AgnerBin LuoLei LiuMing LiuYongde PengShen QuKarolina Amelia StachlewskaGuixia WangGuoyue YuanQiu ZhangYanqiu WangPublished in: Journal of diabetes (2022)
IDegLira is efficacious and well tolerated in Chinese adults with T2D not controlled by OADs.